Clinical Trials Logo

Filter by:
NCT ID: NCT02854709 Completed - Glucose Metabolism Clinical Trials

Effects of Sleep Extension on Glucose Metabolism in Chronically Sleep Deprived Individuals

Start date: July 2016
Phase: N/A
Study type: Interventional

This is a randomized cross over study of the effect of 2-week sleep extension in chronically sleep deprived non-diabetic individuals on glucose metabolism.

NCT ID: NCT02854111 Completed - Diabetes Mellitus Clinical Trials

Using of Ice Cream for Diagnosis of Diabetes Mellitus

Start date: July 2013
Phase: N/A
Study type: Interventional

The overall global prevalence of type 2 diabetes mellitus (DM) is rising. Based on the latest Thai National Health Examination Survey, an estimated 3.2 million people had DM, of whom one-third was undiagnosed. The inexpensive oral glucose tolerance test (OGTT) is a more sensitive and reliable test of DM than fasting plasma glucose (FPG) or HbA1c, and is recommended for diagnosing DM and impaired glucose tolerance (IGT). Although the OGTT provides useful diagnostic information, poor patient tolerance of glucose solutions is inevitable.

NCT ID: NCT02849509 Completed - Atrial Fibrillation Clinical Trials

Patient Convenience Study- NIS RELATE

Start date: June 20, 2016
Phase:
Study type: Observational

The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).

NCT ID: NCT02847598 Completed - Clinical trials for Systemic Lupus Erythematosus

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

LILAC
Start date: October 20, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of the study is to evaluate the efficacy of BIIB059 (litifilimab) in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, including discoid lupus erythematosus (DLE)) with or without systemic manifestations (Part B). The secondary objective is to evaluate additional efficacy parameters of BIIB059 in reducing SLE/CLE disease activity, pharmacokinetic parameters, safety and tolerability of BIIB059 (Parts A and B).

NCT ID: NCT02847416 Completed - Healthy Subjects Clinical Trials

A Study of Pressure and Flow Characteristics During Inspiration and Expiration Using BreatheMAX® in Healthy Subjects

PFBM
Start date: August 2016
Phase: N/A
Study type: Interventional

the aim of this study are to explore the characteristics of mean airway pressure, oscillatory amplitude and power spectral density (PSD) of oscillatory airway pressure that generate by various loaded and flow rate during expiration and inspiration in healthy subjects and to explore the best loaded and flow rate for airway secretion clearance using the BreatheMAX® device

NCT ID: NCT02846129 Completed - Anesthesia Clinical Trials

Incidence of Complications Associated With Anesthesia in Multiple Gestation Undergoing Cesarean Delivery

Start date: October 2016
Phase: N/A
Study type: Observational

Incidence of anesthesia related complications in multiple gestation patients undergoing cesarean delivery has not been reported in Thailand. The aim of this study is to identify complications that occur which may derived from different anesthetic techniques used, such as hypotension, uterine atony, postpartum hemorrhage, rate of hysterectomy, blood transfusion and fetal outcome.

NCT ID: NCT02840682 Completed - Clinical trials for Neonatal Resuscitation

Outcomes of Neonatal Resuscitation

Start date: April 2016
Phase: N/A
Study type: Observational

The primary objective of this study is to describe mortality of newborns who received basic, advanced or no neonatal resuscitation immediately after birth at Shoklo Malaria Research Unit.

NCT ID: NCT02833584 Completed - Dengue Clinical Trials

Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults

Start date: September 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether regular dosage of paracetamol causes transaminitis (hepatitis) and evaluate its potency in the treatment of dengue infection.

NCT ID: NCT02829346 Completed - Clinical trials for Osteoarthritis, Knee

Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty

Start date: October 2012
Phase: Phase 2
Study type: Interventional

This study evaluates the peri-articular tranexamic acid injection in total knee arthroplasty which is an alternative route of administration for blood loss reduction. Half of participants will receive intravenous tranexamic acid injection, while the other half will receive peri-articular tranexamic acid injection during total knee arthroplasty.

NCT ID: NCT02827162 Completed - Dengue Fever Clinical Trials

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Start date: March 29, 2016
Phase:
Study type: Observational

Primary objectives: - To assess how dengue vaccine efficacy varies across participant subgroups regarding polymorphism in human leukocyte antigen (HLA) alleles of interest. - To assess the association between HLA alleles and, serotype-specific neutralization antibody titers and summary neutralization measure in the vaccine and placebo groups. - To assess the association between the polymorphism in HLA alleles of interest and susceptibility to Dengue fever and Dengue Haemorrhagic fever. Secondary objectives: - To assess whether dengue serotype-specific neutralizing antibody titers and associated summary neutralization measure at 28 days post-dose 3 are related to the rate of occurrence of symptomatic Virologically-confirmed dengue infection after post-dose 3 - To evaluate whether the dengue serotype-specific neutralizing antibody and associated summary neutralization measure at 28 days post-dose 3 are related to the level of vaccine efficacy against dengue viruses after post-dose 3.